Back to Back Issues Page
New Drug Combination for Wet AMD Treatment
March 30, 2016

New Drug Combination for Wet AMD Treatment

It's not unusual to use a combination of drug therapies to treat different health conditions. Thanks to a new discovery of how blood vessels develop and then leak, a combination therapy is being studied to treat wet macular degeneration.

Anti-VEGF and Anti-angiopoeitin 2

High levels of vascular endothelial growth factor (VEGF) contribute to the development of abnormal blood vessels that leak which results in loss of central vision. Angiopoietins also belong to the family of vascular growth factors and work alongside VEGF to promote blood and lymph vessels growth in the eye.

Eylea, one of the most current anti-VEGF drugs, will be combined with anti-angiopoietins to be given as a single injection in a clinical trial for those who have choroidal neosvasculariztion (new leaky blood vessels) due to age related macular degeneration. Bayer and Regeneron will be partnering together to provide support to this Phase 2 clinical trial.

“Bayer is strongly committed to further expanding its ophthalmology portfolio with innovative therapies for patients suffering from vision impairment. Addressing multiple pathways offers potential additional benefit to patients with devastating retinal eye diseases,” said Dr. Joerg Moeller, member of the Executive Committee of Bayer AG’s Pharmaceuticals Division and Head of Development.

“Inhibiting the Angiopoietin 2 pathway is a promising new approach for a combination therapy, and we are looking forward to working on it together with Regeneron.”

Find out who is a candidate for this study and where the study sites are located:

Combination Therapy for Wet Macular Degeneration 

Leslie Degner, RN, BSN

Better Health for Better Vision

Back to Back Issues Page